Creso Pharma (ASX:CPH) - Co founder, CEO & Executive Director, Dr Miri Halperin Wernli
Co founder, CEO & Executive Director, Dr Miri Halperin Wernli
Source: Creso Pharma
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Creso Pharma (CPH) has successfully delivered the second shipment of cannaQIX products to Pharma Dynamics South Africa
  • Pharma Dynamics is a subsidiary of Lupin International which is the fifth largest pharmaceutical company in South Africa
  • This delivery saw Creso Pharma pocket CHF220,000 (around A$320,000) which has already been added to the company’s growing revenue portfolio
  • cannaQIX is Creso Pharma’s range of cannabidiol oil-based nutraceuticals which aim to improve stress management and support mental health
  • Shares in CPH are up 3.26 per cent on the back of this news and are trading at 23.8 cents

Creso Pharma (CPH) has successfully delivered the second shipment of cannaQIX products to Pharma Dynamics South Africa.

Pharma Dynamics is a subsidiary of Lupin Internationa,l which is the fifth-largest pharmaceutical company in South Africa.

Currently, it distributes Creso Pharma’s products across South Africa but has plans to extend it throughout Namibia, Lesotho, Mozambique, Zimbabwe, Botswana, Uganda, Angola and Swaziland.

This delivery saw Creso Pharma pocket CHF220,000 (around A$320,000) which has been added to the company’s growing revenue portfolio.

“We are excited about the completion of this second order from Pharma Dynamics which has underpinned a very successful launch of cannaQIX under the Cannamics brand in South Africa,” Commercial Director Jorge Wernli said.

“We are very proud of having accomplished this delivery in spite of the current restrictions in place, mainly due to the COVID situation. We are looking forward to further growth throughout South Africa and other territories together with Pharma Dynamics,” he addd.

cannaQIX is Creso Pharma’s range of cannabidiol oil-based nutraceuticals, which aim to improve stress management and support mental health and nervous functions.

Creso Pharma is now working on a number of new opportunities and partnerships which will be announced in due course.

Shares in CPH are up 3.26 per cent on the back of this news and are trading at 23.8 cents at 1:52 pm AEDT.

CPH by the numbers
More From The Market Online

This stock provides Oz’s only HIV self-test kit – and it’s bullish on the budget

Atomo Diagnostics is the only company in Australia that provides TGA-approved HIV self-test kits. It says…

Recce Pharma heading closer to full efficacy data for flagship R327

Recce Pharma has announced the latest cohort of patients in the company's Phase I/II UTI trial…
The Market Online Video

Breaking barriers in cancer treatment: Race Oncology pioneers a new era with bisantrene

Race Oncology (ASX:RAC) has announced positive results in killing cancer cells in combination with the drug…

Optiscan agreement with Mayo Clinic aims to expedite robotic surgery

Optiscan Imaging is parterning with Mayo Clinic to develop a digital confocal laser endomicroscopic imaging system